New York, New York (PRWEB) May 31, 2014
As morcellator lawsuits (http://www.gynecaremorcellatorlawsuit.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that a medical group in Europe has announced plans to undertake a review of the uterine cancer risks potentially associated with the use of power morcellators in minimally-invasive uterine surgery. According to a statement issued by European Society for Gynaecological Endoscopy on May 3, 2014, the review will look at the potential for power morcellators to spread undetected uterine cancer cells throughout the peritoneal cavity, as well as any other risks possibly associated with such procedures. The Society plans to issue new recommendations regarding the use of morcellators within a few months, once the review is completed. In the meantime, the group has advised that patients be informed about the possible harmful effects of power morcellation.*
“Our Firm has received numerous inquiries from women who are concerned that power morcellation caused their uterine cancers to spread. News of the European review just underscores how serious an issue this is,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering free hysterectomy cancer lawsuit reviews to women who suffered uterine sarcoma or other cancers allegedly spread by morcellation.
Hysterectomy Cancer Lawsuits
Court documents indicate that a number of hysterectomy cancer lawsuits have been filed in U.S. courts on behalf of women who allegedly experienced the spread of undetected uterine cancer because of power morcellation. In February, for example, the husband of a 53-year-old woman who died from uterine cancer less than a year after she underwent power morcellation filed a morcellator lawsuit in the U.S. District Court, Eastern District of Pennsylvania. (Case No. 14 5557) On May 1, 2014 a similar complaint was filed in the U.S. District Court, Western District of New York on behalf of a woman who blames uterine morcellation for the spread of leiomyosarcoma in her abdominal cavity. (Case 6:14-cv-06218) Most recently, a case was filed in the U.S. District Court, Northern District of California on May 13, 2014 that claims the use of a Wolf Power Morcellator promoted the dissemination of uterine cancer cells throughout a woman’s peritoneal cavity. (Case No. Case5:14-cv-02209-PSG)
Power morcellators are surgical tools that are used during laparoscopic hysterectomies and fibroid removal procedures to cut up tissue so that it may be removed via a small incision in the abdomen. On April 17, 2014, the U.S. Food & Drug Administration (FDA) issued an alert discouraging the use of morcellation in uterine surgery because of the risk that it can promote the spread of cancerous cells. The FDA will convene a panel of outside advisors later this summer to investigate the matter further.
Until the FDA can provide further guidance, Johnson & Johnson’s Ethicon unit has suspended sales of its Gynecare Morcellex, Morcellex Sigma Tissue Morcellator System, and Gynecare X-Tract Tissue Morcellator products pending further guidance from the FDA.** A number of hospitals, including the Cleveland Clinic, have also moved to bar or limit the technique while the FDA review continues.***
Women who allegedly experienced the spread of uterine sarcoma or other cancers due to uterine morcellation may be entitled to file their own hysterectomy cancer lawsuit against the manufacturer of the device. To learn more about the risks potentially associated with power morcellation, please visit Bernstein Liebhard LLP's website. Free case reviews can also be obtained by calling 800-511-5092.
*http://www.esge.org/article/218, ESGE, May 3, 2014
**reuters.com/article/2014/04/30/us-johnson-johnson-device-idUSKBN0DG06G20140430, Reuters, April 30, 2014
***cleveland.com/healthfit/index.ssf/2014/04/surgical_tool_for_hysterectomy.html, Cleveland Plain Dealer, April 28, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP